Skip to Content

Fisher & Paykel Healthcare Corp Ltd

FPH: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$54.00XkztvmkLhpfhccfy

Disappointing Homecare Growth and Outlook but Review of Systemic Risk Has Us Raise FVE to NZD 16.40

The transition of coverage to a new analyst and reduction in cost of equity following a review of narrow-moat Fisher & Paykel’s systemic risk exposure has us raising our fair value estimate to NZD 16.40 from NZD 11.00, despite weaker than expected growth reported and a subdued outlook in the homecare division. Based on an AUD/NZD exchange rate of 1.05, our fair value estimate is revised to AUD 15.60 up from AUD 10.70.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of FPH so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center